Latest Conference Articles

AMCP Nexus: Panelists Share Current Scope of Biosimilar Industry

Skylar Jeremias

October 26 2023

Panelists at the Academy of Managed Care Pharmacy (AMCP) Nexus meeting chronicled the current state of the US biosimilar market, including current policies impacting the market, recent regulatory decisions, and the developing arguments around requirements for clinical efficacy studies.

Samsung Bioepis Presents Positive Phase 3 Data on Aflibercept Candidate

Skylar Jeremias

October 9 2023

At EURETINA 2023, Samsung Bioepis shared positive comparative efficacy data on its aflibercept biosimilar candidate, demonstrating that the product is as safe and effective as the originator (Eylea).

Abstracts Highlight Growing Comfortability With Trastuzumab Biosimilars in Breast Cancer

Skylar Jeremias

July 31 2023

Abstracts presented at the annual meeting of the American Society of Clinical Oncology (ASCO 2023) emphasized the safety and efficacy of a trastuzumab biosimilar in treating HER2-positive breast cancer and growing utilization of trastuzumab biosimilars over time.

Why Are Companies Launching Biosimilars With 2 Prices? Julie Reed Explains

Skylar Jeremias,Ashley Gallagher

July 30 2023

Why are companies pricing their adalimumab biosimilars with 2 prices? Can the United States expect more of this pricing strategy for future biosimilar launches? Julie Reed, executive director of the Biosimilars Forum, has the answers.

The Top 3 Policy Initiatives That Could Impact the US Biosimilar Market

Skylar Jeremias,Ashley Gallagher

July 23 2023

Julie Reed, MS, executive director of the Biosimilars Forum, takes a look at the 3 policy initiatives that could have the greatest ramifications for the US biosimilars industry.

Julie Reed: When the US Could See Meaningful Savings From Adalimumab, Ranibizumab Biosimilar Competition

Skylar Jeremias,Ashley Gallagher

June 25 2023

Juliana (Julie) Reed, executive director of the Biosimilars Forum, predicts how long it will take for savings from adalimumab and ranibizumab biosimilar competition to fully manifest and how stakeholders can champion for better market competition for biosimilars.

Dose Rounding Can Reduce Drug Waste Costs Associated With Reference, Biosimilar Bevacizumab

Skylar Jeremias

June 19 2023

Implementing strategies, such as dose rounding, can offset the impact of drug waste and reduce the total cost of care for value-based programs, according to a recent study of practices participating in the Oncology Care Model.

Dr Fran Gregory Discusses the Future Landscape of the Biosimilars Marketplace

Pearl Steinzor

June 7 2023

Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health, discusses what the future biosimilars marketplace may look like compared with generics and reference products at Asembia 2023.

What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends

Skylar Jeremias

May 28 2023

On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.

Biosimilar Acceptance Takes Time but Policy Intervention Is Needed, Panelists Say

Skylar Jeremias

May 25 2023

A group of panelists at Asembia 2023 shared the bigger role that pharmacists, payers, and providers can play in growing biosimilar acceptance and championing policy changes that boost biosimilar utilization.